Literature DB >> 9756723

RANTES expression and contribution to monocyte chemotaxis in arthritis.

M V Volin1, M R Shah, M Tokuhira, G K Haines, J M Woods, A E Koch.   

Abstract

Rheumatoid arthritis (RA) is characterized by recruitment of leukocytes from the vasculature into inflamed synovial tissue (ST) and synovial fluid (SF), which depends, in part, upon the continued maintenance of chemotactic stimuli. RANTES is a potent chemoattractant for leukocytes including monocytes and CD45RO+ memory T lymphocytes. The aim of this study was to determine the production, the source, and the function of antigenic RANTES in arthritis. We detected antigenic RANTES in SFs from RA and OA patients (100 +/- 22.7 and 72 +/- 30.7 pg/ml, respectively). CM from RA ST fibroblasts stimulated with interleukin-1beta or tumor necrosis factor-alpha contained significantly more antigenic RANTES than unstimulated CM (452 +/- 181.6 and 581 +/- 200.2 pg/ml, respectively, versus 12 +/- 4.4 pg/ml, P < 0.05). PHA-stimulated RA SF mononuclear cells secreted 5- to 15-fold more antigenic RANTES than did nonstimulated mononuclear cells, while LPS induced secretion up to 4-fold. We immunolocalized antigenic RANTES to sublining macrophages (28 +/- 3.7 and 8 +/- 2.0% immunopositive cells), perivascular macrophages (56 +/- 6.9 and 19 +/- 3.4%), and synovial lining cells (37 +/- 5.8 and 60 +/- 10.4%) in RA and OA tissue, respectively. Anti-RANTES neutralized 20.2 +/- 1.3% of the RA SF chemotactic activity for normal peripheral blood monocytes (P < 0.05). These results demonstrate antigenic RANTES in RA and OA ST and SF and identify RANTES as a chemoattractant for monocytes in the RA joint. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756723     DOI: 10.1006/clin.1998.4590

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  34 in total

1.  Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody.

Authors:  Pierre Portalès; Sylvie Fabre; Thierry Vincent; Caroline Desmetz; Brigitte Réant; Danièle Noël; Jacques Clot; Christian Jorgensen; Pierre Corbeau
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

Review 2.  The roles of catabolic factors in the development of osteoarthritis.

Authors:  Dominick J Blasioli; David L Kaplan
Journal:  Tissue Eng Part B Rev       Date:  2013-12-11       Impact factor: 6.389

Review 3.  The Multifunctional Role of the Chemokine System in Arthritogenic Processes.

Authors:  Giovanni Bernardini; Giorgia Benigni; Rossana Scrivo; Guido Valesini; Angela Santoni
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

4.  Characterization of Th1- and Th2-associated chemokine receptor expression in spleens of patients with immune thrombocytopenia.

Authors:  Shu-Fen Zhou; Ji Ma; Hui-Ting Qu; Zong-Tang Liu; Wei-Dong He; Juan-Dong Wang; Ai-Xia Dou; Ni Zhang; Jun-Li Liu; Cheng-Shan Guo; Yan Shi; Ming Hou; Jun Peng
Journal:  J Clin Immunol       Date:  2013-03-14       Impact factor: 8.317

5.  3D Printed Multiplexed Competitive Migration Assays with Spatially Programmable Release Sources.

Authors:  Alexander P Haring; Emily G Thompson; Raymundo D Hernandez; Sahil Laheri; Megan E Harrigan; Taylor Lear; Harald Sontheimer; Blake N Johnson
Journal:  Adv Biosyst       Date:  2019-12-05

6.  Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.

Authors:  Alan T Clucas; Ajit Shah; Yuanchao Derek Zhang; Vincent F Chow; Ronald P Gladue
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Chemokines in joint disease: the key to inflammation?

Authors:  J J Haringman; J Ludikhuize; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

8.  The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis.

Authors:  Piotr Adrian Klimiuk; Jacek Kita; Justyna Chwiecko; Stanislaw Sierakowski
Journal:  Clin Rheumatol       Date:  2008-07-29       Impact factor: 2.980

9.  The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.

Authors:  Jan L Bjersing; Kristina Eriksson; Andrej Tarkowski; L Vincent Collins
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

10.  Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.

Authors:  J J Haringman; M C Kraan; T J M Smeets; K H Zwinderman; P P Tak
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.